A novel drug molecule could potentially lead to new treatments to prevent Parkinson's disease in younger patients, according to new research.

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

The cause of Parkinson's Disease remains largely unknown, but a new drug could be extremely beneficial to treat symptoms.

More than 100,000 Canadians currently live with Parkinson's disease. A novel drug molecule being studied by researchers from ...

Researchers at Tel Aviv University cooperated with three major Israeli medical centers to develop a new method for detecting ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new study.

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

People with rare genetic variants linked to degenerative brain disorders like Parkinson's disease are at increased risk of ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

A novel drug molecule could potentially lead to new treatments to prevent Parkinson's disease in younger patients, according ...